Skip to content
★ Sign in to follow
IPCA Laboratories Limited logo

IPCA Laboratories Limited Stock: price and insider trades · India

IN·Mcap ₹440BHealth Care

No insider purchase over the last 90 days. The latest, by Paschim Chemicals Private Limited, was filed 11 Mar 2024.

IPCA Laboratories Limited: what insiders have been doing

IPCA Laboratories Limited, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEBI (PIT + SAST). Over the twelve months to 8 November 2026, 1 filing were filed, from 1 insider.

The flow runs one way only: 1 sale worth €42k, from 1 insider, and no purchase. Biggest ticket of the year: €42k, sold by Manish Kumar Jain and made public on 17 February 2026.

A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

Compared with its exchange (1,987 companies, median 4 filings), a count of 1 filing is below the norm. Looking back to 2021, when coverage begins, insiders filed 1 purchase and 10 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.

Insider Decl.
16
Thresholds
n/a
Buy Volume
€459,850
1 ops. · all time
Sell Volume
€68M
10 ops. · all time

Who traded when

BuySale
Manish Kumar Jain1 sale
Usha M. Chandurkar1 sale
Pawan Kothari1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 10,128 of 26,897 companies
57.7
score / 100
Value
37
Quality
79
FCF yld1.1%
Earn yld2.5%
EV/EBITDA22.7x
ROE13%
Gross mgn69%
Net mgn12%
Debt/EBITDA0.4x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹1,734.20
Analyst consensus
18 analysts
1.65/5
₹1,405.00Target ₹1,733.50(-0%)₹1,980.00
Income statement
Revenue₹95.6B
Gross profit₹65.8B69% margin
EBITDA₹20.7B22% margin
Net income₹11.4B11.8% margin
Valuation
PER (trailing)37.9x
PER (forward)26.4x
P/Book5.5x
Beta0.04
Balance sheet & cash
Market cap₹440B
Total debt₹8.1B
Free Cash Flow₹4.9B
Debt / Equity8%
Profitability & ownership
ROE13.2%
ROA8.4%
% insiders45.1%
% institutions45.2%
Last declaration on 17 February 2026
Declarations16 total
  • ▼
    Executives
    4M INR10SEBI
    3,000 shares@ ₹1,482.2183100.0% of flowEquity SharesSEBI:99c1fa2a3cf0b7341a1f73b84dc84afeebc1f680
  • ▼
    Executives
    3M INR10SEBI
    2,220 shares@ ₹1,413.0216100.0% of flowEquity SharesSEBI:63e5184524765d41c31682fe6123987a95af9949
  • ●
    Related company / holdingExecutives
    0SEBI
    10,187,058 sharesEquity SharesSEBI:ea08648d3ac5da43ea1e3a4796a926d68d06cda6
  • ●
    Related company / holdingExecutives
    0SEBI
    10,173,000 sharesEquity SharesSEBI:52505fe2908d88b3e8d9c4c68b21b861f7f7507c
  • ●
    Related company / holdingExecutives
    0SEBI
    14,058 sharesEquity SharesSEBI:750da4256c5f6e0a644f76f10b6b1a444a8c9bfa
  • ▼
    Executives
    6B INR10SEBI
    4,000,000 shares@ ₹1,499.2458100.0% of flowEquity SharesSEBI:94f0b4a72c1b33668e85acd3c2cd325163b016ba
  • ▲
    Related company / holdingExecutives
    42M INR10SEBI
    35,000 shares@ ₹1,200.9654100.0% of flowEquity SharesSEBI:9b880dfd82a0c6a948d5497f3954a740cdce8f76
    Canonical exit: 9 Jun 2024 (T+90)
  • ▼
    Executives
    22M INR10SEBI
    20,000 shares@ ₹1,081.8467100.0% of flowEquity SharesSEBI:5354172f0889784fc8727cab693fcce0cdbb5502
  • ▼
    Executives
    2M INR10SEBI
    2,000 shares@ ₹874.385100.0% of flowEquity SharesSEBI:983c01f9a9d0d6beaa648cbe73f2726e8ff575c8
  • ●
    Executives
    0SEBI
    4,000,000 sharesEquity SharesSEBI:e1a134883d16b81a955ba52910acc269eead952c
  • ●
    Executives
    0SEBI
    302,000 sharesEquity SharesSEBI:798058b83ec55a85199f0dc14eed461e64ada5d3
  • ▼
    Executives
    21M INR7SEBI
    20,000 shares@ ₹1,026.816846.8% of flowEquity SharesSEBI:c28f7e729b5d591e6c4dbf188f09106e3c73d046
  • ▼
    Executives
    1M INR28SEBI
    450 shares@ ₹2,441.15780.0003% mcap100.0% of flowEquity SharesSEBI:b862456a1a39501f1a37fd82251b03d209e8f714
  • ▼
    Executives
    10M INR25SEBI
    4,000 shares@ ₹2,510.000.0029% mcap100.0% of flowEquity SharesSEBI:cff1f76106c4923f0f9431cd38dd99a7bca9cf6a
  • ▼
    Executives
    24M INR19SEBI
    10,000 shares@ ₹2,421.89790.0071% mcap53.2% of flowEquity SharesSEBI:4059a27a241926da5e5a0a5d531d4575ab345076
  • ▼
    Executives
    4M INR10SEBI
    1,597 shares@ ₹2,383.30240.0011% mcap100.0% of flowEquity SharesSEBI:657f288567c9ecc5b4b94334f2c2e01982d91b1c

16 of 16 declarations

About IPCA Laboratories Limited

IPCA Laboratories Limited is an Indian pharmaceutical company engaged in the manufacturing of generic drugs and pharmaceutical products. It is listed on the Bombay Stock Exchange under the symbol XBOM.